# Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)

> **NCT04823585** · PHASE4 · COMPLETED · sponsor: **Helsinki University Central Hospital** · enrollment: 95 (actual)

## Conditions studied

- Asthma, Aspirin-Induced
- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04823585
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-12
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-01-16
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823585, "Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04823585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*